A COVID-19 candidate protein subunit vaccine.
Potential treatment - pre-clinical evidence
MVC-COV1901 is a COVID-19 candidate protein subunit vaccine being developed by Medigen Vaccine Biologics Corporation/NIAID/Dynavax. It is based on a prefusion SARS-CoV-2 spike immunogen with CpG 1018 (a Th1-biasing synthetic toll-like receptor 9 agonist) and aluminum hydroxide serving as adjuvants (Kuo et al., 2020). Currently, this COVID-19 candidate vaccine is being evaluated in Phase I clinical trial.
S-2P subunit vaccine
|Link||Tested on||Impact factor||Notes||Publication date||DB entry date|
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
mixed substance animal model protein factor
|HEK293-hACE2 cells; Vero E6 cells; female BALB/c and C57BL/6 mice; Wuhan-Hu-1 strain SARS-CoV-2 spike protein pseudovirus; live SARS-CoV-2 (hCoV-19/Taiwan/CGMH-CGU-01/2020, GenBank accession MT192759)||
Used with CpG 1018 (a Th1-biasing synthetic toll-like receptor 9 agonist) and aluminum hydroxide as adjuvants, the candidate vaccine induced high titer of neutralizing antibodies against pseudotyped virus or live SARS-CoV-2 in sera of immunized mice. No serious adverse reactions were noted.
|Draft landscape of COVID-19 candidate vaccines||healthy adults||Jul/28/2020||Aug/06/2020|
|ID||Title||Status||Phase||Start date||Completion date|
|NCT04822025||A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults||Recruiting||Phase 2||May/20/2021||Jan/01/2022|
|NCT04695652||A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult||Active, not recruiting||Phase 2||Dec/30/2020||Jun/01/2022|
|NCT04487210||A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19||Active, not recruiting||Phase 1||Oct/07/2020||Nov/30/2021|